Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
The present invention is directed to a composition or vaccine composition comprising a) an adjuvant component comprising or consisting of at least one immunostimulatory nucleic acid sequence, complexed with a complexing agent; b) an antigen, preferably a protein or peptide antigen and/or a nucleic acid sequence encoding said antigen; and c) a carrier molecule for combined packaging the adjuvant component and the antigen. The present invention is also directed to the first medical use of such a composition or vaccine composition and to the second medical use of such a composition or vaccine composition or components thereof for the treatment of diseases, such as infectious or cancer or tumour diseases as defined herein. The present invention furthermore discloses kits comprising such a composition or vaccine composition.
1. An immune stimulating composition, comprising:
a) an adjuvant component comprising at least one immunostimulatory RNA (isRNA), complexed with a complexing agent, wherein the immunostimulatory RNA is an antigen-encoding mRNA;
b) a mRNA encoding an antigen; and
c) a carrier molecule for combined packaging of the adjuvant component and the nucleic acid encoding the antigen, the carrier molecule having a formula (I):
L-P1-S[S—P2-S] n -S—P3-L
wherein P1 and P3 are different or identical to each other and represent a linear or branched hydrophilic polyethylene glycol (PEG) polymer chain, wherein the hydrophilic PEG polymer chain exhibits a molecular weight of 1 kDa to 100 kDa;
P2 is a cationic or polycationic polypeptide, having a length of 3 to 100 amino acids, and comprising at least 2 cysteine residues;
—S—S— is a (reversible) disulfide bond, wherein one of the sulfur positions of each of the disulfide bonds is provided by the at least 2 cysteine residues of the polypeptide of P2; and
L is an optional ligand and may be selected independent from the other from RGD, Transferrin, Folate, a signal peptide or signal sequence, a localization signal or sequence, a nuclear localization signal or sequence (NLS), an antibody, a cell penetrating peptide, a human immunodeficiency virus TAT peptide, a ligand of a receptor, cytokines, hormones, growth factors, small molecules, carbohydrates, mannose, galactose, synthetic ligands, small molecule agonists, inhibitors or antagonists of receptors, or Arg-Gly-Asp (RGD) peptidomimetic analogues,
wherein n is an integer between 1 and 50.
2. The composition according to claim 1 , wherein the complexing agent of the adjuvant component is a cationic or polycationic compound selected from cationic or polycationic proteins or peptides or cationic or polycationic polymers.
3. The composition according to claim 2 , wherein the complexing agent of the adjuvant component is selected from
an oligopeptide having following sum formula (V):
{(Arg) l ;(Lys) m ;(His) n ;(Orn) o ;(Xaa) x }; (formula (V)
wherein 1+m+n+o+x=3-100, and 1, m, n or o independently of each other is any number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90 and 91-100 provided that the overall content of Arg (Arginine), Lys (Lysine), His (Histidine) and Orn (Ornithine) represents at least 10% of all amino acids of the oligopeptide of formula (V); and Xaa is any amino acid selected from native (=naturally occurring) or non-native amino acids except of Arg, Lys, His or Orn; and x is any number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90, provided, that the overall content of Xaa does not exceed 90% of all amino acids of the oligopeptide of formula (V),
or from a disulfide-crosslinked cationic compound comprising as a repeat unit an oligopeptide having following subformula (Va):
{(Arg) l ;(Lys) m ;(His) n ;(Orn) o ;(Xaa′) x (Cys) y }; formula (Va)
wherein (Arg) l ;(Lys) m ;(His) n ;(Orn) o ; and x is preferably are as defined above for formula (V), Xaa′ is any amino acid selected from native (=naturally occurring) or non-native amino acids except of Arg, Lys, His, Orn or Cys and y is any number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80 and 81-90, provided that the overall content of Arg (Arginine), Lys (Lysine), His (Histidine) and Orn (Ornithine) represents at least 10% of all amino acids of the oligopeptide,
or from a disulfide-crosslinked cationic compound comprising as a repeat unit an oligopeptide having following subformula (Vb):
Cys 1 {(Arg) l ;(Lys) m ;(His) n ;(Orn) o ;(Xaa) x }Cys 2 ; (formula (Vb))
wherein component {(Arg) l ;(Lys) m ;(His) n ;(Orn) o ;(Xaa) x } (formula (V)) within formula (Vb) is as defined herein and forms a core of subformula (Vb), and wherein Cys 1 and Cys 2 are Cysteines proximal to, or terminal to (Arg) l ;(Lys) m ;(His) n ;(Orn) o ;(Xaa) x .
4. The composition according to claim 1 , wherein the at least one immunostimulatory RNA to the complexing agent has a nitrogen/phosphate ratio (N/P) of about 0.01-4.
5. The composition according to claim 1 , wherein the antigen is selected from tumour antigens, pathogenic antigens, animal antigens, viral antigens, protozoan antigens, bacterial antigens, allergic antigens, autoimmune antigens, and allergens.
6. The composition according to claim 1 , wherein all components of the composition have a nitrogen/phosphate ratio (N/P) of about 0.01-2.
7. The composition according to claim 1 , wherein the complexing agent of the adjuvant component is protamine.
8. The composition according to claim 5 , wherein the antigen is a tumour antigen.
9. The composition according to claim 5 , wherein the antigen is a viral antigen.
10. The composition according to claim 5 , wherein the antigen is a bacterial antigen.
11. The composition according to claim 1 , wherein the mRNA encoding an antigen and the immunostimulatory RNA of the adjuvant component have the same nucleic acid sequence.
12. A kit, comprising a composition according to claim 1 in one or more parts of the kit, and optionally comprising instructions for use of the kit.